About Twelve Bio
Twelve Bio is a company based in Copenhagen (Denmark) founded in 2019 by Stefano Stella and Guillermo Montoya was acquired by Ensoma in January 2023.. Twelve Bio has raised $2.57 million across 2 funding rounds from investors including Ensoma. The company has 10 employees as of December 31, 2021. Twelve Bio offers products and services including Engenious Platform. Twelve Bio operates in a competitive market with competitors including Senti Biosciences, Poseida Therapeutics, ADARx Pharmaceuticals, CRISPR Therapeutics and Aldevron, among others.
- Headquarter Copenhagen, Denmark
- Employees 10 as on 31 Dec, 2021
- Founders Stefano Stella, Guillermo Montoya
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ensoma Aps
-
Annual Revenue
-
Net Profit
$-412.66 K (USD)-63as on Dec 31, 2022
-
EBITDA
$-493.27 K (USD)-57as on Dec 31, 2022
-
Total Equity Funding
$2.57 M (USD)
in 2 rounds
-
Latest Funding Round
$2.57 M (USD), Seed
Sep 18, 2020
- Investors
-
Employee Count
10
as on Dec 31, 2021
-
Acquired by
Ensoma
(Jan 05, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Twelve Bio
Twelve Bio offers a comprehensive portfolio of products and services, including Engenious Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform that combines delivery and DNA editing for disease treatments.
Funding Insights of Twelve Bio
Twelve Bio has successfully raised a total of $2.57M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2.57 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Seed — $2.6M
- First Round First Round
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Seed - Twelve Bio | Valuation |
investors |
|
| May, 2020 | Amount | Seed - Twelve Bio | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Twelve Bio
Twelve Bio has secured backing from 1 investor. Prominent investors backing the company include Ensoma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provider of in vivo stem cell modification technologies and vector-based drug delivery tool
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Twelve Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Twelve Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Twelve Bio Comparisons
Competitors of Twelve Bio
Twelve Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Poseida Therapeutics, ADARx Pharmaceuticals, CRISPR Therapeutics and Aldevron, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts
|
|
| domain | founded_year | HQ Location |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing.
|
|
| domain | founded_year | HQ Location |
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
|
|
| domain | founded_year | HQ Location |
Therapeutics for molecular-level cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Twelve Bio
When was Twelve Bio founded?
Twelve Bio was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is Twelve Bio located?
Twelve Bio is headquartered in Copenhagen, Denmark.
Who is the current CEO of Twelve Bio?
Stefano Stella is the current CEO of Twelve Bio. They have also founded this company.
Is Twelve Bio a funded company?
Twelve Bio is a funded company, having raised a total of $2.57M across 2 funding rounds to date.
How many employees does Twelve Bio have?
As of Dec 31, 2021, the latest employee count at Twelve Bio is 10.
What does Twelve Bio do?
Twelve Bio was established in 2019 as a spin-off from the Montoya group in Copenhagen, Denmark. Focus is placed on CRISPR-Cas12a, a protein that functions as a biological tool for detecting and modifying DNA sequences to generate new variants. Diagnostics and therapeutics are created using this technology. Support has been provided by organizations including the BioInnovation Institute, Novo Nordisk Fonden, and Novo Holdings. Operations center on biotechnology applications in healthcare.
Who are the top competitors of Twelve Bio?
Twelve Bio's top competitors include CRISPR Therapeutics, Senti Biosciences and Poseida Therapeutics.
What products or services does Twelve Bio offer?
Twelve Bio offers Engenious Platform.
Who are Twelve Bio's investors?
Twelve Bio has 1 investor. Key investors include Ensoma.
What is Twelve Bio's valuation?
The valuation of Twelve Bio is $6.93M as of Sep 2020.